To evaluate characteristics of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) initiating subcutaneous efgartigimod (SC-EFG).

Since June 2024 approval of SC-EFG for treatment of adults with CIDP in the United States (US), evidence is still limited around how SC-EFG is utilized within the CIDP treatment paradigm. A preliminary real-world study in early 2025 described early SC-EFG initiators; this is an updated analysis as of August 2025.

Adults with CIDP who initiated SC-EFG were identified from US medical and pharmacy claims (based on information licensed from IQVIA: Longitudinal Access and Adjudication Data [LAAD] for the period May 2018 – August 2025, reflecting estimates of real-world activity [all rights reserved]). Adults initiating SC-EFG between 06/21/2024 and 08/31/2025 with a CIDP diagnosis (and no myasthenia gravis diagnosis) within 1 year before SC-EFG initiation were selected (first SC-EFG claim as index). Eligible patients had ≥1 year of quarterly claims activity before index. Patient demographics and CIDP treatment utilization were assessed in the 1 year before index.

Majority of SC-EFG initiators with CIDP had neuropathic pain and prior exposure to CIDP therapies, reflecting high disease burden. Yet, a substantial subset had not received any CIDP treatment in the preceding year, highlighting the potential role of SC-EFG in addressing both treated and undertreated patient populations.